ERBB2 and breast cancer: A loss of HER2 expression in recurrent BC, e.g., HER2-positive to HER2-low or HER2-0, HER2-low to HER2-0, correlated significantly with a better OS (Hazard ratio 0.533, 95% CI 0.32–0.90, p = 0.018).